Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Rationale: Pulmonary arterial hypertension (PAH) is a vasculopathy characterized by enhanced pulmonary artery (PA) smooth muscle cell (PASMC) proliferation and suppressed apoptosis. Decreased expression of microRNA-204 has been associated to this phenotype. By a still elusive mechanism, microRNA-204 downregulation promotes the expression of oncogenes, including nuclear factor of activated T cells, B-cell lymphoma 2, and Survivin. In cancer, increased expression of the epigenetic reader bromodomain-containing protein 4 (BRD4) sustains cell survival and proliferation. Interestingly, BRD4 is a predicted target of microRNA-204 and has binding sites on the nuclear factor of activated T cells promoter region. Objective: To investigate the role of BRD4 in PAH pathogenesis. Methods and Results: BRD4 is upregulated in lungs, distal PAs, and PASMCs of patients with PAH compared with controls. With mechanistic in vitro experiments, we demonstrated that BRD4 expression in PAH is microRNA-204 dependent. We further studied the molecular downstream targets of BRD4 by inhibiting its activity in PAH–PASMCs using a clinically available inhibitor JQ1. JQ1 treatment in PAH–PASMCs increased p21 expression, thus triggering cell cycle arrest. Furthermore, BRD4 inhibition, by JQ1 or siBRD4, decreased the expression of 3 major oncogenes, which are overexpressed in PAH: nuclear factor of activated T cells, B-cell lymphoma 2, and Survivin. Blocking this oncogenic signature led to decreased PAH-PASMC proliferation and increased apoptosis in a BRD4-dependent manner. Indeed, pharmacological JQ1 or molecular (siRNA) inhibition of BRD4 reversed this pathological phenotype in addition to restoring mitochondrial membrane potential and to increasing cells spare respiratory capacity. Moreover, BRD4 inhibition in vivo reversed established PAH in the Sugen/hypoxia rat model. Conclusions: BRD4 plays a key role in the pathological phenotype in PAH, which could offer new therapeutic perspectives for patients with PAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“Just like BRD4, BRD2 and BRD3 bind to acetylated histones and are found on genes promoters associated with chromatin remodelers and transcription factors.(16,24,40) BRD2 and BRD4 are often associated to cell cycle control and inflammation in multiple inflammatory diseases and cancers, although the role of BRD3 in the…”
Pulmonary Arterial Hypertension in France: Results from a National Registry
Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaici, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1668oc · Cited by 2,000
Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects
Larsen, S., Nielsen, J., Hansen, C. N., Nielsen, L. B., Wibrand, F., Stride, N., Schroder, H. D., Boushel, R., Helge, J. W., Dela, F., et al. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2012.230185 · Cited by 1,180
Pulmonary Arterial Hypertension
Badesch, D. B., Raskob, G. E., Elliott, C. G., Krichman, A. M., Farber, H. W., Frost, A. E., Barst, R. J., Benza, R. L., Liou, T. G., Turner, M., et al. (2010) · Chest · doi:10.1378/chest.09-1140 · Cited by 1,178
Benza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A. E., & McGoon, M. D. (2012) · Chest · doi:10.1378/chest.11-1460 · Cited by 1,104 · cited 1×
“their prognosis remains poor with a 3-year survival of 55% to 65%.(4,6,7) As in cancer, PAH is associated with sustained DNA”
Mechanisms of disease: pulmonary arterial hypertension
Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., & Grimminger, F. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.87 · Cited by 800 · cited 1×
“tery wall, leading to increased pulmonary vascular resistance, right ventricular (RV) failure and death.(1) PAH is a rare disease with an estimated prevalence of 15 to 50 cases/million(2) and its prevalence is thought to be highly underestimated”
An epidemiological study of pulmonary arterial hypertension
Peacock, A. J., Murphy, N. F., McMurray, J. J. V., Caballero, L., & Stewart, S. (2007) · European Respiratory Journal · doi:10.1183/09031936.00092306 · Cited by 792
BET domain co-regulators in obesity, inflammation and cancer
Belkina, A. C., & Denis, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3256 · Cited by 711 · cited 3×
“Just like BRD4, BRD2 and BRD3 bind to acetylated histones and are found on genes promoters associated with chromatin remodelers and transcription factors.(16,24,40) BRD2 and BRD4 are often associated to cell cycle control and inflammation in multiple inflammatory diseases and cancers, although the role of BRD3 in the…”
Interleukin-6 Overexpression Induces Pulmonary Hypertension
Steiner, M. K., Syrkina, O. L., Kolliputi, N., Mark, E. J., Hales, C. A., & Waxman, A. B. (2009) · Circulation Research · doi:10.1161/circresaha.108.182014 · Cited by 655
NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
Brown, J. D., Lin, C. Y., Duan, Q., Griffin, G., Federation, A. J., Paranal, R. M., Bair, S., Newton, G., Lichtman, A. H., Kung, A. L., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.024 · Cited by 614
Cited by
The cancer theory of pulmonary arterial hypertension
Boucherat, O., Vitry, G., Trinh, I., Paulin, R., Provencher, S., & Bonnet, S. (2017) · Pulmonary Circulation · doi:10.1177/2045893217701438 · Cited by 202
Self-citationOmura, J., Habbout, K., Shimauchi, T., Wu, W.-H., Breuils-Bonnet, S., Tremblay, E., Martineau, S., Nadeau, V., Gagnon, K., Mazoyer, F., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047626 · Cited by 164
Self-citationEpigenetic Changes in Diabetes and Cardiovascular Risk
Keating, S. T., Plutzky, J., & El-Osta, A. (2016) · Circulation Research · doi:10.1161/circresaha.116.306819 · Cited by 139
“BETs have been reported to take part in directing transcriptional programs involved in pulmonary arterial hypertension.(144) In terms of atherosclerosis, BET inhibitors repress leukocyte adhesion and transendothelial migration in vitro and ex vivo and decrease atherosclerotic lesions in LDL receptor–deficient mice in…”
Fahey, J. M., Stancill, J. S., Smith, B. C., & Girotti, A. W. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000443 · Cited by 59
Metadata
- Authors
- Meloche, J., Potus, F., Vaillancourt, M., Bourgeois, A., Johnson, I., Deschamps, L., Chabot, S., Ruffenach, G., Henry, S., Breuils-Bonnet, S., Tremblay, È., Nadeau, V., Lambert, C., Paradis, R., Provencher, S., & Bonnet, S.
- Venue
- Circulation Research
- Published
- 2015-08-28
- Volume
- 117
- Issue
- 6
- Pages
- 525-535
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W1932584694
- Cited by
- 183
- References
- 50
- FWCI
- 11.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.